Article By:
Lipper Alpha Insight
Monday, September 9, 2019 9:05 PM EDT
The lucrative deal with Sumitomo is just the treatment Roivant needs to keep its model ticking. But it’s unlikely to fix what ails its Japanese partner.
In this article: DNPUF